ArticleThoracic cancer2025

Anlotinib Plus Osimertinib in Osimertinib-Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study.

Yu Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.